Abstract
Objective: The objective of present investigation was to develop rivastigmine tartrate transdermal film employing factorial design.Methods: The formulations were designed by Design-Expert software-version10. A series of films were prepared by solvent casting method using polymers, plasticizer, permeation enhancer and other solvents. Transdermal films were evaluated for flatness, drug content, tensile strength, in vitro drug release and ex vivo skin permeation study.Results: The flatness was found 100% (percentage) for all film formulations. The drug content of transdermal film was found in the range of 96.51±0.2 to 98.81±0.3%. The tensile strength of transdermal film was found in the range of 6.28±0.06 to 11.56±0.03 N/mm2 (newton/millimeter2) and in vitro drug release at 24th h (hour) was found in the range of 86.24±0.25 to 96.1±0.48%% for various formulations and ex vivo skin permeation study results at 24th h was found in the range of 85.83±0.74 to 97.36±0.93%.Conclusion: These results support the feasibility of developing transdermal film of rivastigmine tartrate for human applications. Thus, transdermal delivery of rivastigmine tartrate film is a safe, painless and cost effective drug delivery system for Alzheimer’s patients.
Highlights
Alzheimer’s disease (AD) is the most common form of dementia among older people, accounting for 50-70% of the cases [1, 2]
Dementia is a broader term than AD and refers to any acquired brain syndrome resulting in deteriorating mental functions, severe enough to impair the individual’s normal daily life situation [3]
External phase was added to internal phase solution and 10 ml of 70 % aqueous ethanol was added to above solution and the mixture was homogenized for 15 min at 2000 rpm, and sonicated for 10 min
Summary
Alzheimer’s disease (AD) is the most common form of dementia among older people, accounting for 50-70% of the cases [1, 2]. In the past thirty years, there has been an explosion in the creation and discovery of new medicinal agents. Innovations in drug delivery have enabled successful implementation of these pharmaceuticals, and promoted the developments of new medical treatments with existing drugs. The creation of a transdermal drug delivery system (TDDS) has been one of the most important innovations. Transdermal products for cardiovascular disease, Parkinson’s disease, Alzheimer’s disease, depression, anxiety, skin cancer, and post-menopausal bone loss are at various stages of formulation and development [4,5,6,7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
